Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Autor: Nicholls, Stephen J., Bhatt, Deepak L, Buse, John B, Prato, Stefano Del, Kahn, Steven E, Lincoff, A Michael, McGuire, Darren K, Nauck, Michael A, Nissen, Steven E, Sattar, Naveed, Zinman, Bernard, Zoungas, Sophia, Basile, Jan, Bartee, Amy, Miller, Debra, Nishiyama, Hiroshi, Pavo, Imre, Weerakkody, Govinda, Wiese, Russell J, D'Alessio, David
Zdroj: In American Heart Journal January 2024 267:1-11
Databáze: ScienceDirect
Externí odkaz: